Your browser is no longer supported. Please, upgrade your browser.
ATNM [AMEX]
Actinium Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.59 Insider Own1.55% Shs Outstand15.43M Perf Week1.81%
Market Cap116.59M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float13.38M Perf Month-26.82%
Income-20.40M PEG- EPS next Q-0.37 Inst Own26.70% Short Float7.93% Perf Quarter-29.63%
Sales- P/S- EPS this Y34.20% Inst Trans20.73% Short Ratio2.01 Perf Half Y-37.51%
Book/sh2.94 P/B2.87 EPS next Y23.70% ROA-64.60% Target Price- Perf Year2.55%
Cash/sh3.49 P/C2.42 EPS next 5Y- ROE-78.00% 52W Range4.71 - 19.47 Perf YTD8.08%
Dividend- P/FCF- EPS past 5Y30.50% ROI- 52W High-56.70% Beta1.08
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low78.98% ATR0.55
Employees25 Current Ratio10.50 Sales Q/Q- Oper. Margin- RSI (14)38.72 Volatility4.81% 5.83%
OptionableYes Debt/Eq0.00 EPS Q/Q70.40% Profit Margin- Rel Volume0.83 Prev Close8.30
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume527.65K Price8.43
Recom1.80 SMA20-9.07% SMA50-19.47% SMA200-13.80% Volume436,047 Change1.57%
Nov-05-20Initiated Alliance Global Partners Buy $25
Dec-06-17Initiated B. Riley FBR, Inc. Buy $2.75
Oct-23-17Resumed ROTH Capital Buy $6
Sep-14-17Initiated Maxim Group Buy $3
Aug-25-16Initiated ROTH Capital Buy $5
Feb-29-16Initiated H.C. Wainwright Buy $8
Oct-15-15Initiated FBR Capital Outperform $12
Oct-01-14Initiated MLV & Co Buy $16
Jul-22-14Initiated Canaccord Genuity Buy $16
Jan-13-21 07:00AM  
Dec-29-20 08:30AM  
Dec-23-20 05:45PM  
Dec-17-20 05:45PM  
Dec-09-20 05:45PM  
08:00AM  
Dec-08-20 08:00AM  
Dec-07-20 08:30AM  
08:15AM  
07:00AM  
Dec-03-20 07:00AM  
Dec-02-20 08:49PM  
05:45PM  
Dec-01-20 07:00AM  
Nov-23-20 07:00AM  
Nov-20-20 05:45PM  
Nov-19-20 07:30AM  
Nov-16-20 07:00AM  
Nov-13-20 05:45PM  
Nov-11-20 08:00AM  
Nov-04-20 12:21PM  
12:13PM  
12:00PM  
Oct-29-20 11:30AM  
Oct-28-20 07:00AM  
Oct-22-20 05:45PM  
Oct-21-20 08:04AM  
07:00AM  
Oct-14-20 07:00AM  
Oct-09-20 06:37AM  
Oct-08-20 05:45PM  
Oct-06-20 07:00AM  
Oct-02-20 05:45PM  
Sep-23-20 07:00AM  
Sep-14-20 07:00AM  
Sep-10-20 07:00AM  
Aug-31-20 06:05PM  
Aug-28-20 11:30AM  
Aug-26-20 08:48AM  
Aug-12-20 11:30AM  
Aug-10-20 02:30PM  
12:00PM  
Aug-04-20 05:45PM  
Aug-03-20 11:54AM  
Jul-28-20 05:50PM  
Jul-27-20 11:30AM  
Jul-23-20 12:00PM  
Jul-21-20 08:57AM  
Jul-20-20 10:32AM  
Jul-15-20 07:03AM  
Jul-09-20 11:30AM  
Jul-08-20 09:05AM  
Jun-19-20 05:15PM  
Jun-17-20 11:30AM  
Jun-16-20 11:30PM  
04:01PM  
Jun-15-20 11:29PM  
Jun-12-20 08:43AM  
Jun-09-20 08:47AM  
Jun-04-20 09:45PM  
09:42AM  
Jun-03-20 09:53AM  
Apr-24-20 05:15PM  
Apr-21-20 11:35PM  
04:01PM  
Apr-16-20 07:00AM  
Apr-12-20 09:02AM  
Mar-06-20 10:56AM  
Mar-05-20 07:30AM  
Feb-26-20 07:33AM  
Feb-25-20 09:33AM  
Feb-21-20 07:30AM  
Feb-13-20 08:03AM  
Feb-05-20 05:50PM  
08:03AM  
Jan-30-20 05:45PM  
Jan-13-20 12:00PM  
07:15AM  
07:03AM  
Jan-07-20 07:03AM  
Jan-03-20 11:30AM  
Jan-02-20 09:29AM  
Dec-22-19 05:08PM  
Dec-09-19 06:10AM  
06:00AM  
Dec-07-19 08:35AM  
Dec-01-19 09:30AM  
Nov-20-19 09:00AM  
Nov-07-19 04:05PM  
Nov-06-19 09:15AM  
09:00AM  
Oct-28-19 08:20AM  
Oct-15-19 10:48AM  
Sep-30-19 08:00AM  
Sep-23-19 08:00AM  
Sep-16-19 08:00AM  
Jul-23-19 08:00AM  
Jul-17-19 12:56PM  
Jul-11-19 08:00AM  
Jun-26-19 08:00AM  
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, developing Antibody Radiation-Conjugates (ARCs). The ARCs selectively kill patient's cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies or gene therapy to enable engraftment of these transplanted cells with minimal toxicities. It also offers Iomab-B (I-131 apamistamab), which is in a phase III study for Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning. The company is also developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.